
Mazen Noureddin, MD, MHSc, discusses phase 2 data for GSK’s once-monthly efimosfermin presented at The Liver Meeting 2026, including fibrosis marker results in patients with compensated cirrhosis.

Mazen Noureddin, MD, MHSc, is a professor of medicine at Houston Methodist Hospital and an internationally recognized leader in steatotic liver disease (SLD) and SLD-related cirrhosis. He founded the Houston Research Institute and serves as chief scientific officer and co-chairman of the board of Summit Clinical Research Solutions. He has led or participated in more than 100 clinical trials and has authored more than 350 peer-reviewed publications, including in The New England Journal of Medicine, The Lancet, and Nature Medicine. In 2026, he received the inaugural Impact Award from the American Association for the Study of Liver Diseases.

Mazen Noureddin, MD, MHSc, discusses phase 2 data for GSK’s once-monthly efimosfermin presented at The Liver Meeting 2026, including fibrosis marker results in patients with compensated cirrhosis.